(Q43177434)

English

Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist

scientific article published on 2 February 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 November 2017

Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist (English)

1 reference

Europe PubMed Central

15 November 2017

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Brendan M Johnson

1

1 reference

Europe PubMed Central

15 November 2017

Laurel M Adams

2

1 reference

Europe PubMed Central

15 November 2017

Ke Zhang

3

1 reference

Europe PubMed Central

15 November 2017

Shelby D Gainer

4

1 reference

Europe PubMed Central

15 November 2017

Lyndon C Kirby

5

1 reference

Europe PubMed Central

15 November 2017

Robert A Blum

6

1 reference

Europe PubMed Central

15 November 2017

Glen Apseloff

7

1 reference

Europe PubMed Central

15 November 2017

Royce A Morrison

8

1 reference

Europe PubMed Central

15 November 2017

Ralph A Schutz

9

1 reference

Europe PubMed Central

15 November 2017

Peter F Lebowitz

10

1 reference

Europe PubMed Central

15 November 2017

publication date

2 February 2010

1 reference

Europe PubMed Central

15 November 2017

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

15 November 2017

50

1 reference

Europe PubMed Central

15 November 2017

8

1 reference

Europe PubMed Central

15 November 2017

951-959

1 reference

Europe PubMed Central

15 November 2017

Treatment of nausea and vomiting: gaps in our knowledge.

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353761

21 January 2018

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353761

21 January 2018

Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting.

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353761

21 January 2018

ASPAN'S evidence-based clinical practice guideline for the prevention and/or management of PONV/PDNV.

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353761

21 January 2018

Consensus guidelines for managing postoperative nausea and vomiting

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353761

21 January 2018

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353761

21 January 2018

Disposition and metabolism of radiolabeled casopitant in humans

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353761

21 January 2018

Pharmacokinetics and brain penetration of casopitant, a potent and selective neurokinin-1 receptor antagonist, in the ferret

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353761

21 January 2018

Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353761

21 January 2018

The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353761

21 January 2018

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353761

21 January 2018

Rifampin drastically reduces plasma concentrations and effects of oral midazolam.

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353761

21 January 2018

The significance of QT interval in drug development

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353761

21 January 2018

Identifiers

10.1177/0091270009353761

1 reference

Europe PubMed Central

15 November 2017

release_bevnahqqgjd4tcichhzoohqbze

1 reference

https://api.fatcat.wiki/v0/release/bevnahqqgjd4tcichhzoohqbze

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

15 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43177434&oldid=2144517668"